SecBot SecBot
Biotech Drug Report Generated Jul 2, 2026

MT-001

INM·InMed Pharmaceuticals Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Preclinical (IND-enabling)
Time to market
Unknown, still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
Why 4/10
MT-001 is a preclinical-stage asset. The nearest catalyst is the first-in-human regulatory filing (IND/CTA) expected mid-2026, a procedural milestone, not a data readout. Phase 2a proof-of-concept data isn't due until 2028 (>12 months away). The stock already repriced ~100%+ on the May 2026 reverse-merger announcement. A regulatory filing is unlikely to drive a major second leg, hence 4.
Actionable Insight NEUTRAL

MT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.

Price Chart

Loading chart...

Executive Summary

MT-001 is a preclinical-stage anti-PACAP monoclonal antibody for migraine prevention, discovered by Paragon Therapeutics and being advanced by Mentari Therapeutics. Mentari is reverse-merging into InMed Pharmaceuticals (NASDAQ: INM) in a deal backed by a $290M PIPE led by Fairmount that funds operations through 2028. The PACAP pathway was recently validated by Lundbeck's bocunebart, which succeeded in Phase 2b trials. However, MT-001 has no human data yet; first-in-human filings are expected mid-2026 and Phase 2a proof-of-concept data not until 2028. Competition is intensifying from Lundbeck (more advanced), Slate Medicines ($130M funded), and Vedana. The stock surged ~100%+ on the merger news, but MT-001 itself is years from a value-changing catalyst.

How It Works

MT-001 is a monoclonal antibody (a manufactured protein that mimics the immune system's ability to fight targets) designed to block PACAP, a signaling protein involved in migraine. PACAP is a newly validated target that works through a different biological pathway than the current standard-of-care CGRP inhibitors. By blocking PACAP, MT-001 aims to prevent migraine attacks, especially in the ~40-50% of patients who don't respond well to existing anti-CGRP therapies. It is designed for subcutaneous (under-the-skin) injection for patient convenience.

Trial Status

MT-001 is in preclinical development. Discovered by Paragon Therapeutics, it has demonstrated equal or superior in vitro potency vs. benchmark antibodies, with favorable pharmacokinetic profiles in non-human primates. First-in-human regulatory filings (IND/CTA) are expected mid-2026. Phase 1 trials would follow, with Phase 2a proof-of-concept data projected for 2028.

The Two-Sided Case

▲ Bull Case5
PACAP is a newly validated migraine target, Lundbeck's bocunebart (also anti-PACAP) succeeded in a Phase 2b study, de-risking the mechanism (source: fiercebiotech.com)
The $290M oversubscribed PIPE (led by Fairmount, with a16z, Janus Henderson, Commodore Capital) funds operations through 2028, unusual depth for a preclinical asset (source: biospace.com)
Designed for convenient subcutaneous dosing with best-in-class claims based on in vitro potency vs. benchmarks (source: inmedpharma.com press release)
Addresses a large unmet need, ~40-50% of migraine patients have suboptimal response to anti-CGRP therapies, and PACAP is a distinct orthogonal pathway (source: investing.com)
MT-002 (bispecific CGRP×PACAP) provides a pipeline-in-a-product follow-on if PACAP monotherapy works (source: biopharmadive.com)
▼ Bear Case5
No human data exists, MT-001 is still preclinical and has not filed an IND. Phase 2a data is not expected until 2028, years away from any pivotal catalyst (source: benzinga.com)
Earlier anti-PACAP programs failed: Amgen's AMG 301 (PAC1 receptor antagonist) and Eli Lilly's LY3451838 both flopped in Phase 2 (source: p05.org)
Intense competition, Lundbeck's bocunebart is already in Phase 2b with positive data; Slate Medicines launched with $130M; Vedana debuted with $46M; all targeting PACAP (source: fiercebiotech.com, biopharmadive.com)
INM currently has a ~$2-5M market cap with bearish analyst consensus (0 Buy, 3 Hold, 4 Sell, 1 Strong Sell) and a history of Nasdaq delisting risk
Massive dilution risk, the reverse merger gives Mentari shareholders majority control; pre-merger INM shareholders receive only contingent value rights; Armistice Capital also holds dilutive options repriced to $0.80 (source: SEC 8-K filings)

Upcoming Catalysts

  • Mid-2026: First-in-human regulatory filing (IND/CTA) for MT-001
  • By Dec 31, 2026: Expected close of InMed-Mentari reverse merger, new Nasdaq ticker
  • Q1 2027: Phase 1 healthy volunteer data for MT-002 (bispecific)
  • 2028: Phase 2a proof-of-concept data for MT-001

Source Filing

The SecBot filing or press-release report that triggered this drug report:

InMed Pharmaceuticals Inc. S-4 INM ·Originating report

Sources · 15

Hover a chip for the title
1 inmedpharma.com2 biospace.com3 biopharmadive.com4 benzinga.com5 mentaritx.com6 in.investing.com7 citybiz.co8 fiercebiotech.com9 biopharmcatalyst.com10 biotechsnap.com11 sec.gov12 sec.gov13 synapse.patsnap.com14 newsletter.biobucks.co15 americanpharmaceuticalreview.com